Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock Has Consensus Price Target of $5.83

by · The Markets Daily

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Free Report) have earned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $5.83.

Several analysts have recently issued reports on the stock. Lake Street Capital dropped their target price on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Alliance Global Partners restated a “buy” rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Finally, Weiss Ratings downgraded shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th.

Get Our Latest Research Report on Sensus Healthcare

Insider Transactions at Sensus Healthcare

In other news, Director Eric Sachetta acquired 27,304 shares of the business’s stock in a transaction on Monday, August 31st. The stock was bought at an average cost of $3.54 per share, for a total transaction of $96,656.16. Following the purchase, the director owned 294,784 shares in the company, valued at approximately $1,043,535.36. This represents a 10.21% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders bought 120,171 shares of company stock valued at $405,230. Insiders own 10.20% of the company’s stock.

Hedge Funds Weigh In On Sensus Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in the company. North Star Investment Management Corp. purchased a new stake in shares of Sensus Healthcare during the first quarter worth approximately $500,000. Bank of New York Mellon Corp acquired a new stake in shares of Sensus Healthcare in the second quarter valued at $303,000. BlackRock Inc. acquired a new stake in shares of Sensus Healthcare in the second quarter valued at $252,000. Finally, EP Wealth Advisors LLC purchased a new position in Sensus Healthcare in the second quarter valued at $49,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Price Performance

Shares of SRTS stock opened at $2.93 on Tuesday. The company has a market cap of $48.23 million, a price-to-earnings ratio of -3.12 and a beta of 1.18. The stock has a 50 day simple moving average of $3.11 and a 200-day simple moving average of $3.29. Sensus Healthcare has a 1-year low of $2.66 and a 1-year high of $5.49.

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). The business had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $4.60 million. Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%.

About Sensus Healthcare

(Get Free Report)

Sensus Healthcare, Inc (NASDAQ: SRTS) develops and markets non-invasive medical devices for dermatology and oncology. The company’s primary focus is superficial radiation therapy, a low-energy X-ray treatment designed to treat conditions affecting or located near the surface of the skin.

Its product portfolio includes the SRT-100 system and related platforms, which are used primarily in the treatment of non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as keloid scars.

Recommended Stories